|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Thresholds for identifying ambulatory hypertension (daytime systolic BP [SBP]/diastolic BP [DBP] ≥135/85 mm Hg, 24-hour SBP/DBP ≥130/80 mm Hg, and nighttime SBP/DBP ≥120/70 mm Hg) have been derived from European, Asian, and South American populations.
|
28428231 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
The participants were classified into three groups: hypertension (HTN), high normal BP, and normal BP, and also into SBP and DBP quintiles.
|
29210861 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Each interquartile increment in walkability was associated with the lower blood pressure outcomes of DBP (β = -0.358, 95% CI: -0.42, -0.29 mmHg), SBP (β = -0.833, 95% CI: -0.95, -0.72 mmHg) as well as reduced hypertension risk (RR = 0.970, 95% CI: 0.96, 0.98).
|
29398408 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In addition, we found that systolic pressure (SBP; 129.32 ± 14.86 mmHg, <i>p</i> = 0.041), body mass index (BMI; 22.54 ± 2.71, <i>p</i> = 0.046), and low-density lipoprotein (LDL; 3.09 ± 0.98 mmol/L, <i>p</i> = 0.048) in the subjects with PES were significantly higher than those measurements in the CN subjects (SBP; 122.06 ± 10.55 mmHg; BMI; 20.24 ± 2.13; LDL; 2.91 ± 0.76 mmol/L), and there was a significant negative correlation between an increased adult hypertension risk and a shorter LTL.
|
29085308 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In 'fit' participants, the decline in SBP was 12.4 (95% confidence interval 11.9-13.0) mmHg/decade in those treated for hypertension and 8.5 (7.8-9.1) mmHg in those not treated.
|
28441696 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
ERA significantly reduced 24-h ambulatory blood pressure and sitting blood pressure in patients with hypertension [5 trials, 24-h SBP: WMD -7.65 (-8.95 to -6.36), 24-h DBP: WMD -5.92 (-7.50 to -4.33); 18 trials, SBP: WMD -6.12 (-7.87 to -4.36), DBP: WMD -3.81 (-4.82 to -2.80)].
|
27808564 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
In this cross-sectional study, 200 outpatients (161 women, 39 men) with essential HTN (systolic blood pressure [SBP] ≥ 140 mmHg and diastolic blood pressure [DBP] ≥ 90 mmHg) were recruited from August to November 2012.
|
28318434 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
In addition, short-term exposures to four (PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>2</sub>, NO<sub>2</sub>), two (PM<sub>2.5</sub> and SO<sub>2</sub>), and four air pollutants (PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>2</sub>, and NO<sub>2</sub>), were significantly associated with hypertension (ORs: 1.05-1.10), SBP (β values: 0.53-0.75 mmHg) and DBP (β values: 0.15-0.64 mmHg), respectively.
|
29331891 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was defined as SBP at least 130 mmHg or DBP at least 80 mmHg, taking antihypertensive medicine or self-report.
|
31356404 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
We assessed the role of SBP VVV on the development of CKD in patients with type 2 diabetes (T2D) and hypertension in real life.
|
30817462 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Further logistic analysis indicated that the irisin level was positively correlated with SBP and an independent predictor for hypertension after adjustment.
|
31133682 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
These trials - SPYRAL OFF-MED, RADIANCE SOLO and SPYRAL ON-MED - using newer technologies, demonstrate a 5-10 mmHg incremental reduction in ambulatory SBP from RDN against sham-control, in patients with mild-to-moderate hypertension taking 0-3 drugs.
|
31268917 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
An increase of 0.1 in NDVI corresponded to a reduction in SBP of 1.39 mmHg (95% CI: 1.86, -0.93) and lower odds of hypertension (OR = 0.76, 95% CI: 0.69, 0.82).
|
31672364 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Participants with hypertension but without diabetes (N = 1167) were randomized to an SBP target below 120 mm Hg (intensive treatment) vs a target below 140 mm Hg (standard treatment).
|
31840813 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Stage 2 hypertension (SBP/DBP ≥ 140/90 mmHg) showed significant associations with cardiovascular disease and all-cause mortality, while elevated blood pressure (SBP 120-129 mmHg and DBP < 80 mmHg) showed null associations.
|
31288541 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Forty-one patients with and 82 patients without intradialytic hypertension (intradialytic SBP rise ≥10 mm Hg to > 150 mm Hg) matched in a 1: 2 ratio for age, sex, and hemodialysis vintage were included.
|
30347395 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Prespecified analyses of the Enhanced Control of Hypertension and Thrombolysis Stroke Study for patients enrolled in both arms: (i) low-dose (0.6 mg/kg body weight) or standard-dose (0.9 mg/kg) alteplase and (ii) intensive (target systolic BP [SBP] 130-140 mm Hg) or guideline-recommended (target SBP <180 mm Hg) BP management.
|
31812956 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
The impact of DBP on the risk of developing hypertension compared with optimal BP (SBP <120 mm Hg and DBP <80 mm Hg) was significantly greater than that of SBP in subjects younger than 50 years (hazard ratios, 17.5 for isolated diastolic high-normal vs 10.5 for isolated systolic high-normal [P<.001]; 8.0 for isolated diastolic normal vs 4.1 for isolated systolic normal [P<.001]).
|
28444926 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Wrist circumference, a marker of insulin resistance, is associated with increased SBP in overweight/obese children and adolescents, suggesting a role of insulin resistance in the pathogenesis and development of hypertension.
|
29335612 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
This randomized-cross-over study included 38 patients (age: 60.4 ± 11.1 years, male: 65.8%) with intradialytic hypertension (intradialytic-SBP increase ≥ 10 mmHg at ≥4 over 6 consecutive sessions).
|
30622317 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Childhood hypertension and elevated blood pressure were defined as SBP and/or DBP ≥95th and ≥90th age- and gender-specific percentile, respectively.
|
31826379 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
The genetic risk score, calculated as the sum of BP-increasing alleles of FGF5-rs16998073, CYP17A1-rs11191548, CYP17A1-rs1004467 and MTHFR-rs17367504, was significantly associated with increased SBP (1.16 mmHg/allele, P = 9.01E-5), DBP (0.51 mmHg/allele, P = 4.40E-4) and hypertension risk (OR = 1.22/allele, P = 2.74E-7).
|
20852445 |
2011 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Participants in the bottom 30% (ie, SBP decreased on standing) were significantly older, had a greater prevalence of hypertension and peripheral vascular disease, had higher values of SBP, and had more cigarette-years of smoking.
|
10334798 |
1999 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In a univariate logistic regression analysis hypertension and clinic SBP were not associated with revealed symptoms.
|
31157741 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Pre- and undiagnosed-hypertension was defined as systolic blood pressure/ diastolic blood pressure (SBP/DBP) of 120-139/80-89 mm Hg and SBP⩾140 mm Hg and/or DBP⩾90 mm Hg, respectively, in participants without a history of hypertension and use of antihypertensive medication.
|
27654328 |
2017 |